BlossomHill Therapeutics, Inc. (BLSM) vs Monopar Therapeutics Inc. (MNPR)
A side-by-side comparison of BlossomHill Therapeutics, Inc. and Monopar Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BLSM
BlossomHill Therapeutics, Inc.
$17.29HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
MNPR
Monopar Therapeutics Inc.
$79.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BLSM vs MNPR
growth of $100 · dividends reinvested · last 1yBLSM +24.6% (+24.6%/yr)MNPR -34.9% (-34.9%/yr)BLSM compounded faster over this window
BLSM MNPR
BLSM vs MNPR: by the numbers
- •MNPR is the larger company ($533M vs $503M market cap).
Metrics side by side
Valuation
| Metric | BLSM | MNPR |
|---|---|---|
| P/B ratio | N/A | 4.07 |
Profitability
| Metric | BLSM | MNPR |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | N/A | -13.64% |
| ROIC | -43.41% | -16.89% |
Growth (annualized)
| Metric | BLSM | MNPR |
|---|---|---|
| Total return CAGR (5Y) | N/A | 27.38% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.